Athersys to ask Nasdaq for another reprieve on delisting its stock

Cleveland regenerative medicine startup has been restructuring to cut costs since mid-2022 while raising money to complete clinical trials of its MultiStem adult stem cell therapy.

Charlotte’s largest architecture firms

Fastest-growing Central Ohio credit unions

Northside Hospital Gwinnett expects to create 3,000 jobs from 17-story tower

‘I’m not done’: Freddy’s co-founder continues to impact Wichita, industry

Atlanta homebuilding giant PulteGroup fires incoming COO for alleged Twitter bots

GLY breaks ground on $63M senior living project in Redmond

Birmingham senior living facility property acquired for $9M

Cleveland Whiskey plans to acquire neighboring building in Flats’ South Bank

Athersys to ask Nasdaq for another reprieve on delisting its stock

Previous Centene Corp. executive named chief customer experience officer

Next OneOncology to sell in deal valued at $2.1 billion

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

Courtyard hotel at 9th and F to close for renovations

Colorado cities try to keep up as Airbnbs, other short-term rentals multiply

Commerce Trust picks up $1.2B in new KC client money in 2018

IPO raises funds to look for oil and gas on Salinas property

Cameron Mitchell Restaurants sets Cento opening date

Could SoDo’s industrial corridor be Orlando’s next billion-dollar redevelopment opportunity?

MENU

FirstStar Group

More Stories

John Trowbridge returns to AGH

Previous Centene Corp. executive named chief customer experience officer

Next OneOncology to sell in deal valued at $2.1 billion

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories